By blocking cell growth and triggering programmed cell loss of life or apoptosis.

Experts at Karolinska Institutet and Karolinska University Hospital in Sweden have finally obtained results from the first exams utilizing a new substance that can restore the function of defective p53 and activate apoptosis in tumor cells. The compound is known as APR-246 and has been tested on human beings in a phase I/II study, that was conducted on 22 patients with advanced prostate or bloodstream cancer. A few of the patients originated from the Haematology Centre at the Karolinska University Medical center in, Stockholm, where the study’s lead investigator, consultant Dr S-ren Lehmann is situated.Rivaroxaban also reduced the secondary composite efficacy end stage of loss of life from any cause, myocardial infarction, or stroke, as compared with placebo, with rates of 9.2 percent and 11.0 percent, respectively . Furthermore, rivaroxaban reduced the chance of stent thrombosis , as compared with placebo, with rates of 2.3 percent and 2.9 percent, respectively . The reduction in the principal efficacy end stage with rivaroxaban was consistent among the subgroups except for patients with a history of stroke or transient ischemic attack . In the analysis of both doses of rivaroxaban, each of the doses reduced the primary efficacy end stage of death from cardiovascular causes, myocardial infarction, or stroke, as compared with placebo, with rates in patients receiving the 2 2.5-mg dose of 9.1 percent and 10.7 percent, respectively and prices in patients receiving the 5-mg dosage of 8.8 percent and 10.7 percent, respectively .